Douglas M. Willis

Array ( [id] => 16915760 [patent_doc_number] => 20210188852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => COMPOUNDS AND THEIR METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/464468 [patent_app_country] => US [patent_app_date] => 2017-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -178 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915747 [patent_doc_number] => 20210188839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => COMPOUNDS AND THEIR METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/464467 [patent_app_country] => US [patent_app_date] => 2017-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -124 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750268 [patent_doc_number] => 20180141923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => SELECTIVE HDAC1,2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 15/820827 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15820827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993599 [patent_doc_number] => 20190315757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/462794 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16462794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15540783 [patent_doc_number] => 10570156 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors [patent_app_type] => utility [patent_app_number] => 15/818044 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36276 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15818044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17526823 [patent_doc_number] => 11299494 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-a modulators [patent_app_type] => utility [patent_app_number] => 16/461479 [patent_app_country] => US [patent_app_date] => 2017-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15819 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16461479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17207729 [patent_doc_number] => 11168088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof [patent_app_type] => utility [patent_app_number] => 16/338379 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22852 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16338379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12584823 [patent_doc_number] => 20180086770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => METHOD FOR PRODUCNG TRICYCLIC COMPOUND, AND TRICYCLIC COMPOUND CAPABLE OF BEING PRODUCED BY SAID PRODUCTION METHOD [patent_app_type] => utility [patent_app_number] => 15/809269 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15809269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14664991 [patent_doc_number] => 10370386 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Substituted quinolines as inhibitors of KRAS G12C [patent_app_type] => utility [patent_app_number] => 15/805716 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 57736 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 453 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15805716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14261789 [patent_doc_number] => 10280447 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-07 [patent_title] => Substituted imidazo[1,2-A]pyrazines tethered to energy acceptors [patent_app_type] => utility [patent_app_number] => 15/800649 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 11147 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 246 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15800649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14867803 [patent_doc_number] => 20190284143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => NOVEL PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER AND INFLAMMATORY DISEASES [patent_app_type] => utility [patent_app_number] => 16/347480 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13814375 [patent_doc_number] => 10183948 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-22 [patent_title] => N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists [patent_app_type] => utility [patent_app_number] => 15/796028 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 22567 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15796028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16604704 [patent_doc_number] => 10905687 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Substituted piperazines as ROR-gamma modulators [patent_app_type] => utility [patent_app_number] => 16/344919 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 26800 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16344919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16604705 [patent_doc_number] => 10905688 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors [patent_app_type] => utility [patent_app_number] => 16/345136 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36883 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 580 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864661 [patent_doc_number] => 20190282572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES [patent_app_type] => utility [patent_app_number] => 16/345157 [patent_app_country] => US [patent_app_date] => 2017-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13746743 [patent_doc_number] => 10166296 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Haptens of aripiprazole [patent_app_type] => utility [patent_app_number] => 15/789824 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12808 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15789824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15512681 [patent_doc_number] => 10562916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => Substituted quinoxalines as PDE-10 inhibitors [patent_app_type] => utility [patent_app_number] => 15/787880 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62327 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 524 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15787880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14684787 [patent_doc_number] => 20190241508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => PD-CATALYZED GAMMA-C(SP3)-H ARYLATION / HETEROARYLATION OF FREE AMINES [patent_app_type] => utility [patent_app_number] => 16/344092 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 208 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16344092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14171585 [patent_doc_number] => 10259787 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists [patent_app_type] => utility [patent_app_number] => 15/784560 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45969 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 399 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15784560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641007 [patent_doc_number] => 20180105500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => NOVEL INHIBITORS OF TRANSFORMING GROWTH FACTOR KINASE AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/720731 [patent_app_country] => US [patent_app_date] => 2017-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15720731 [rel_patent_id] =>[rel_patent_doc_number] =>)